The webcast replay will be available after the conclusion of the presentation.
- The webcast replay will be available after the conclusion of the presentation.
- Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases.
- This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug candidates.
- PRN2246/SAR442168 is a covalent BTK inhibitor which crosses the blood-brain barrier and is partnered with Sanofi.